ECM30 Antibody

What is ECM1 and what are its key structural domains?

ECM1 (Extracellular Matrix Protein 1) is a secreted glycoprotein widely expressed across different tissues and organs. The protein contains several important domains:

• ECM1 has tandem repeat domains and a C-terminal domain

• These domains contain crucial CCX6-7CX10-11C motifs (where X represents any amino acid)

• These motifs enable ligand binding to members of the albumin family

• The motifs form either two (in ECM-1b) or three (in ECM-1a) "double loop" structures

Mature human ECM-1a shows significant amino acid identity with corresponding isoforms from other mammals: 69% with mouse, 71% with rat, 72% with canine, and 76% with bovine ECM-1, indicating evolutionary conservation of this protein .

What are the established applications for ECM1 antibodies in research?

Based on validated research protocols, ECM1 antibodies have proven effective in multiple experimental applications:

• Western blot analysis: Effective for detecting ECM1 in cell lysates from COLO 205 human colorectal adenocarcinoma cells and SK-Mel-28 human malignant melanoma cells, with specific bands detected at approximately 75 kDa under reducing conditions

• Immunohistochemistry: Successfully employed for localizing ECM1 in paraffin-embedded tissue sections, particularly effective in colon cancer tissue samples where ECM1 was detected in the plasma membrane of epithelial cells

• Simple Western™ analysis: Allows for automated capillary-based detection of ECM1 at approximately 90 kDa

• Immunoprecipitation: Enables isolation and study of ECM1 protein complexes

How is ECM1 involved in biological functions and disease mechanisms?

ECM1 performs several crucial roles in normal physiology and disease states:

• Acts as a "biological glue" in the dermis, maintaining dermal structure integrity

• Demonstrates angiogenic activity, particularly important in tumor development

• Is overexpressed in many malignant epithelial tumors, suggesting its role in cancer progression

• Mutations in ECM1, particularly within the first tandem repeat domain, are causative in lipoid proteinosis - a condition characterized by thickened and irregular extracellular matrix within connective tissue

• In autoimmune lichen sclerosis, auto-antibodies primarily recognize the second tandem repeat or C-terminus of ECM1

• Interacts with extracellular matrix molecules including fibulin-1 and perlecan through its N-terminal and second tandem repeat domains

• Has been implicated in endocrine resistance in ER+ breast cancers

What are the critical considerations for validating ECM1 antibody specificity?

Rigorous validation of ECM1 antibodies is essential for generating reliable research data:

• Include appropriate positive controls: COLO 205 human colorectal adenocarcinoma and SK-Mel-28 human malignant melanoma cell lines have been validated as expressing detectable levels of ECM1

• Implement negative controls: Always include samples where primary antibody is omitted, with only secondary antibody application to confirm specificity

• Validate across multiple techniques: Compare results from western blotting, immunohistochemistry, and immunoprecipitation to ensure consistent detection

• Verify domain specificity: If working with domain-specific ECM1 antibodies, confirm that they recognize the intended ECM1 domains through epitope mapping or competitive binding assays

• Assess cross-reactivity: Test antibodies against tissues from different species to determine species specificity, noting that human ECM1 shares 69-76% amino acid identity with ECM1 from other mammals

How can researchers generate domain-specific antibodies against ECM1?

The development of domain-specific antibodies provides greater precision for investigating ECM1 functions:

• Prokaryotic expression systems have been successfully employed to generate immunogens for anti-ECM1 antibody production

• Hybridoma technology can be utilized to create monoclonal antibodies targeting specific ECM1 domains

• Six strains of monoclonal antibodies against human ECM1 have been successfully generated, demonstrating high sensitivity and specificity

• These domain-specific antibodies can be characterized through epitope mapping to confirm their target regions within the ECM1 protein

• The generated antibodies should be extensively validated for western blot, immunoprecipitation, and immunohistochemistry applications

What techniques are most effective for studying ECM1 in cancer research?

ECM1 has significant implications in cancer biology, necessitating specialized research approaches:

• Immunohistochemistry protocols: For paraffin-embedded tumor tissue sections, optimal results are obtained using 15 μg/mL of anti-ECM1 antibody with overnight incubation at 4°C, followed by appropriate secondary antibody and detection systems

• Functional neutralization studies: Some monoclonal antibodies against ECM1 demonstrate neutralizing activities that inhibit proliferation, migration, and metastasis in cancer cell lines such as MDA-MB-231

• Protein interaction assays: Techniques to investigate ECM1's interactions with other extracellular matrix components, particularly relevant in cancer microenvironment studies

• Genetic approaches: Analysis of ECM1 mutations and expression patterns across different cancer types can provide insights into its role in tumor progression

What are the optimal conditions for ECM1 antibody storage and handling?

Proper antibody maintenance is critical for research reproducibility:

• Storage recommendations: Use a manual defrost freezer and avoid repeated freeze-thaw cycles

• Long-term storage: -20°C to -70°C for up to 12 months from date of receipt as supplied

• Short-term storage: 2°C to 8°C under sterile conditions after reconstitution for up to 1 month

• Extended storage: -20°C to -70°C under sterile conditions after reconstitution for up to 6 months

• Reconstitution: Use appropriate buffers and adhere to sterile techniques during antibody preparation

How can researchers overcome challenges in detecting ECM1 across different sample types?

Different experimental contexts require optimized approaches:

• For western blotting: Using 1 μg/mL of anti-ECM1 antibody under reducing conditions with Immunoblot Buffer Group 1 has shown effective detection in cancer cell lines

• For Simple Western™ analysis: 10 μg/mL of antibody with 12-230 kDa separation system provides optimal results

• For tissue sections: Chromogenic IHC staining protocols with HRP-DAB systems and hematoxylin counterstaining enable clear visualization of ECM1 localization

• For difficult tissues: Optimize antigen retrieval methods, incubation times, and detection systems based on specific tissue characteristics

What considerations are important when developing ECM1-targeting antibody-drug conjugates (ADCs)?

Leveraging ECM1 antibodies for targeted therapeutics requires specialized knowledge:

• Target selection criteria: ECM1 expression patterns must be thoroughly characterized to ensure tumor specificity and minimize off-target effects

• Internalization kinetics: The rate and extent of ECM1 antibody internalization are critical factors affecting ADC efficacy

• Drug-to-antibody ratio (DAR): An optimal DAR of 3-4 is generally recommended; lower ratios may deliver insufficient drug while higher ratios can cause antibody aggregation and reduced antigen affinity

• Binding affinity considerations: Most effective ADCs have dissociation constant (KD) values in the range of 0.1 to 1 nM, balancing tumor retention with adequate distribution throughout the tumor tissue

How can ECM1 antibodies be utilized to investigate dermatological conditions?

ECM1's role in skin biology offers interesting research opportunities:

• In lipoid proteinosis: ECM1 antibodies can help characterize mutations within the first tandem repeat domain that lead to thickened and irregular extracellular matrix

• In lichen sclerosis: ECM1 antibodies targeting the second tandem repeat or C-terminus can help identify autoantibody binding sites

• In aging skin research: ECM1 antibodies can help investigate ECM1's interactions with other extracellular matrix components like collagen and elastin, which are essential for healthy skin

• In wound healing studies: ECM1 detection can provide insights into ECM remodeling during the wound healing process

What emerging technologies can enhance ECM1 antibody research?

Advanced methodologies are expanding the capabilities of ECM1 research:

• Single-cell analysis: Combining ECM1 antibodies with single-cell techniques can reveal heterogeneity in ECM1 expression across cell populations

• Super-resolution microscopy: Enhanced visualization of ECM1 localization and interactions at the nanoscale level

• Multiplexed imaging: Simultaneous detection of ECM1 alongside other markers to understand contextual protein interactions

• CRISPR-based approaches: Genome editing can help create cellular models with modified ECM1 for functional studies in conjunction with antibody-based detection

How can researchers distinguish between different ECM1 isoforms using antibodies?

Isoform-specific detection requires specialized approaches:

• Western blot analysis: ECM1a and ECM1b can potentially be distinguished by their molecular weights (varying due to different numbers of double-loop structures)

• Domain-specific antibodies: Monoclonal antibodies targeting domains that differ between isoforms (like those containing two versus three double-loop structures) can provide isoform specificity

• Validation with recombinant proteins: Using purified recombinant versions of specific ECM1 isoforms as positive controls

• Genetic knockdown validation: Selective knockdown of specific isoforms can confirm antibody specificity